J&J Innovation Announces Opening of Offices - - BioPharm International

ADVERTISEMENT

J&J Innovation Announces Opening of Offices



Johnson & Johnson (J&J) Innovation, a division of J&J reported the formation of a network of partnering offices across UK life science clusters. The offices function as extensions of its London Innovation Center to work with academics and entrepreneurs throughout the UK to identify early-stage innovation and support the translation of research into new products for patients.

While the London Innovation Center continues to be the primary hub for interactions with the academic and entrepreneurial community in the greater London area, these new partnering offices are part of a broader strategy to interact
more directly with life science “hotspots” throughout the UK and Europe. Johnson & Johnson Innovation is establishing partnering offices in the following locations that will function as a base for interactions throughout the regions:

  • Babraham Research Campus for the wider Cambridge area
  • University of Oxford Old Road Campus for the wider Oxford area
  • The University of Manchester Innovation Center (UMIC) for the North and Midlands
  • Edinburgh BioQuarter for Scotland and Northern Irelan
  • Life Sciences Hub Wales in Cardiff for Wales and the South West.

Representatives from the J&J Innovation Center in London will establish a regular presence in each of the partnering offices that are expected to be fully operational in early 2014.

Johnson & Johnson Innovation focuses on accelerating early innovation and enhancing opportunities for collaboration and investment across Johnson & Johnson’s global healthcare businesses.

Source: Johnson & Johnson

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines

Click here